Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America

Eduardo Lopez-Medina, Mario Melgar, James T Gaensbauer, Ananda S Bandyopadhyay, Bhavesh R Borate, William C Weldon, Ricardo Rüttimann, Joel Ward, Ralf Clemens, Edwin J Asturias, Eduardo Lopez-Medina, Mario Melgar, James T Gaensbauer, Ananda S Bandyopadhyay, Bhavesh R Borate, William C Weldon, Ricardo Rüttimann, Joel Ward, Ralf Clemens, Edwin J Asturias

Abstract

Background: Since April 2016 inactivated poliovirus vaccine (IPV) has been the only routine source of polio type 2 protection worldwide. With IPV supply constraints, data on comparability of immunogenicity and safety will be important to optimally utilize available supplies from different manufacturers.

Methods: In this multicenter phase IV study, 900 Latin American infants randomly assigned to six study groups received three doses of bOPV at 6, 10 and 14weeks and either one IPV dose at 14weeks (groups SP-1, GSK-1 and BBio-1) or two IPV doses at 14 and 36weeks (groups SP-2, GSK-2 and BBio-2) from three different manufacturers. Children were challenged with mOPV2 at either 18 (one IPV dose) or 40weeks (two IPV doses) and stools were collected weekly for 4weeks to assess viral shedding. Serum neutralizing antibodies were measured at various time points pre and post vaccination. Serious adverse events and important medical events (SAE and IME) were monitored for 6months after last study vaccine.

Results: At week 18, 4weeks after one dose of IPV, overall type 2 seroconversion rates were 80.4%, 80.4% and 73.3% for SP-1, GSK-1 and BBio-1 groups, respectively; and 92.6%, 96.8% and 88.0% in those who were seronegative before IPV administration. At 40weeks, 4weeks after a second IPV dose, type 2 seroconversion rates were ≥99% for any of the three manufacturers. There were no significant differences in fecal shedding index endpoint (SIE) after one or two IPV doses (SP: 2.3 [95% CI: 2.1-2.6]); GSK: 2.2 [1.7-2.5]; BBio 1.8 [1.5-2.3]. All vaccines appeared safe, with no vaccine-related SAE or IME.

Conclusion: Current WHO prequalified IPV vaccines are safe and induce similar humoral and intestinal immunity after one or two doses. The parent study was registered with ClinicalTrials.gov, number NCT01831050.

Keywords: Humoral immunity; Intestinal immunity; Poliovirus; Vaccination.

Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Flow chart of the six study groups showing attrition to the Per Protocol populations for immunogenicity and shedding analyses.
Fig. 2
Fig. 2
Rate of excretion (%) of poliovirus type 2 by IPV manufacturer and days post challenge with mOPV2.

References

    1. Patel M., Orenstein W.A. World free of polio – the final steps. N Engl J Med. 2016;374:501–503.
    1. Bandyopadhyay A.S., Garon J., Seib K., Orenstein W.A. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791–808.
    1. Global Polio Eradication Initiative. Polio Eradication & Endgame Strategic Plan 2013-2018. Geneva, Switzerland: World Health Organization; 2013. <> [accessed 23.01.17].
    1. World Health Organization Polio vaccines: WHO position paper – March, 2016. Wkly Epidemiol Rec. 2016;91:145–168.
    1. World Health Organization. SAGE discussion and statement in relation with the IPV supply situation. <> [accessed 23.01.17].
    1. Asturias E.J., Bandyopadhyay A.S., Self S., Rivera L., Saez-Llorens X., Lopez E. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158–169.
    1. O’Ryan G.M., Bandyopadhyay A.S., Villena R., Espinoza M., Novoa J., Weldon W.C. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015;15:1273–1282.
    1. Walker E., Nowacki A.S. Understanding equivalence and noninferiority testing. J Gen Intern Med. 2010;26:192–196.
    1. Ramakrishnan M.A. Determination of 50% endpoint titer using a simple formula. World J Virol. 2016;5:85–86.
    1. Faden H., Modlin J.F., Thoms M.L., McBean A.M., Ferdon M.B., Ogra P.L. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis. 1990;162:1291–1297.
    1. McBean A.M., Thoms M.L., Albrecht P., Cuthie J.C., Bernier R., The Field Staff and Coordinating Committee. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol. 1988;128:615–628.
    1. Halsey N.A., Blatter M., Bader G., Thoms M.L., Willingham F.F., O'Donovan J.C. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine. Pediatr Infect Dis J. 1997;16:675–679.
    1. Modlin J.F., Halsey N.A., Thoms M.L., Meschievitz C.K., Patriarca P.A. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J Infect Dis. 1997;175(suppl. 1):S228–S234.
    1. Yeh S.H., Partridge S., Marcy S.M., Howe B., Curry E.S., Stone M. A randomized study of the safety and immunogenicity of DTPa-HB-IPV vaccine administered as three doses or in a sequential IPV/OPV schedule at 2, 4, and 6 months of age [Abstract] Pediatr Res. 1998;43:161A.
    1. Feldman S. Interchangeability of vaccines. Pediatr Infect Dis J. 2001;20:S23.
    1. Hampton L.M., Farrell M., Ramirez-Gonzalez A., Menning L., Shendale S., Lewis I. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:934–938.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren